Skip to content
Tablet (Extended Release) Allopathic

Upacit XR 15 mg tablet (extended release)

Generic: Upadacitinib

Company: Not listed yet. Prices are as listed on BestinMeds; your pharmacy price may differ.

Strength15 mg
PackBox of 10: 2000.00 taka

Reviewed by: not listed yet. Source: not listed yet.

Last updated September 7, 2024.

Compare

Same generic, same strength

Sorted by price per tablet (extended release). Ask your pharmacist before you switch brands.

Upadacitinib 15 mg tablet (extended release)s

Prices as listed on BestinMeds.

2 brands listed
Upacit XR, box of 10 (this medicine)200.00 taka per tablet (extended release)
Upanib, box of 10280.00 taka per tablet (extended release)

Advertisement

Google Ads 970 x 250
Google Ads 300 x 250
Medicine guide

About this medicine

What this medicine is for, how to take it, and what to watch for.

Read the full Upadacitinib guide

Indications

Rheumatoid arthritis Upadacitinib is a Janus kinase (JAK) inhibitor indicated for the treatment of adults with moderate to severe active rheumatoid arthritis who have had an inadequate response or intolerance to methotrexate.

Dosage and administration

The recommended dose of Upadacitinib is 15 mg once daily. Upadacitinib may be used as monotherapy or in combination with methotrexate or other non-biologic DMARDs. Avoid initiation or interrupt Upadacitinib if absolute lymphocyte count is less than 500 cells/mm3, absolute neutrophil count is less than 1000 cells/mm3 or hemoglobin level is less than 8 g/dL. Pediatric Use: The safety and efficacy of Upadacitinib in children and adolescents aged 0 to 18 years have not yet been established. No data are available.

Side effects

Adverse reactions (greater than or equal to 1%) are: upper respiratory tract infections, nausea, cough, and pyrexia.

Precautions and warnings

Serious Infections: Avoid use of Upadacitinib in patients with active, serious infection, including localized infections. Malignancy: Consider the risks and benefits of Upadacitinib treatment prior to initiating therapy in patients with a known malignancy. Thrombosis: Consider the risks and benefits prior to treating patients who may be at increased risk of thrombosis. Promptly evaluate patients with symptoms of thrombosis and treat appropriately. Gastrointestinal Perforations: Use with caution in patients who may be at increased risk. Laboratory Monitoring: Recommended due to potential changes in lymphocytes, neutrophils, hemoglobin, liver enzymes and lipids. Embryo-Fetal Toxicity: Upadacitinib may cause fetal harm based on animal studies. Advise females of reproductive potential of the potential risk to a fetus and to use effective contraception. Vaccinations: Avoid use of Upadacitinib with live vaccines.

Pregnancy and lactation

The limited human data on use of Upadacitinib in pregnant women are not sufficient to evaluate a drug-associated risk for major birth defects or miscarriage. Based on animal studies, upadacitinib has the potential to adversely affect a developing fetus. Advise not to breastfeed.

Clinical details

BestinMeds shares medicine information to help you compare. It does not replace advice from your doctor or pharmacist.

Advertisement

Google Ads 970 x 250
Google Ads 300 x 250

Advertisement

Google Ads 970 x 250
Google Ads 300 x 250